Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.
Moderna (NASDAQ: MRNA) delivered one piece of bad news to investors a few months ago: Chief medical officer (CMO) Tal Zaks will depart in September. The news came during the initial rollout of Moderna's very first product: its coronavirus vaccine. Moderna allayed investor fears this week, however.
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.